Vutrisiran Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 25mg/0.5ml
Reference Brands: Amvuttra (USA/EU)
Category:
Orphan Drugs
Vutrisiran (Amvuttra) is an RNA interference (RNAi) therapeutic used to treat polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. It works by silencing the transthyretin (TTR) gene, reducing the production of abnormal TTR protein that forms amyloid deposits. The medication is administered as a subcutaneous injection (25 mg/0.5 mL) once every 3 months under medical supervision, helping to slow disease progression and improve quality of life in patients with this rare condition.
Vutrisiran is available in Injection
and strengths such as 25mg/0.5ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vutrisiran is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vutrisiran can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing